Ziritaxestat
Ziritaxestat (GLPG1690) is a small molecule autotaxin inhibitor. It has been investigated in a Phase 2 clinical trial for idiopathic pulmonary fibrosis (IPF) . Preclinical studies in vitro and in animal models have demonstrated its role in targeting the LPA pathway relevant to fibrotic diseases.
Product Specifications
CAS Number
1628260-79-6
Product Name Alternative
Autotaxin, Inhibitor, GLPG1690, GLPG-1690, GLPG 1690, inhibit, Ziritaxestat, Phosphodiesterase (PDE), phosphodiesterase
Field of Research
Metabolism Research
Purity
97.00% (May vary between batches)
Solubility
10% DMSO+40% PEG300+5% Tween 80+45% Saline:2 mg/mL (3.4 mM) ; DMSO:50 mg/mL (84.93 mM) ; H2O:< 0.1 mg/mL (insoluble)
Smiles
CCc1nc2c (C) cc (cn2c1CNc1nc (c (s1) C#N) -c1ccc (F) cc1) N1CCN (CC (=O) N2CC (O) C2) CC1
Molecular Formula
C30H33FN8O2S
Molecular Weight
588.7
Storage Conditions
-20°C
Notes
For research use only.
Available Sizes
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
DCAF12L2 CRISPRa sgRNA lentivector (set of three targets)(Mouse)
